Compugen Third Quarter 2017 Conference Call Scheduled for Tuesday, November 7, 2017 at 10:00 AM ET

Wednesday, October 25, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

HOLON, Israel, October 25, 2017 /PRNewswire/ --

Compugen Ltd. (NASDAQ: CGEN), a leader

in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that the Company will release its third quarter financial results on Tuesday, November 7, 2017 before the U.S.
financial markets open. Management will host a live webcast to review the results and provide a corporate update at 10:00 AM ET.

To access the live conference call by telephone, please dial 1-888-281-1167 from the US, or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

About Compugen  Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact:  Elana Holzman Director, Investor Relations and Corporate Communications Compugen Ltd. Email: [email protected] Tel: +972 (3) 765-8124

SOURCE Compugen Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store